Real-World Effectiveness of Primary Series and Booster Doses of Inactivated Coronavirus Disease 2019 Vaccine Against Omicron BA.2 Variant Infection in China: A Retrospective Cohort Study

• Published in: The Journal of infectious diseases Vol. 228; no. 3; pp. 261 - 269
• Main Authors: Tang, Lin, Wang, Fu-Zhen, Rodewald, Lance E, Wang, Xuan-Yi, Liu, Si-Yu, Liu, Qian-Qian, Wang, Xiao-Qi, Wu, Dan, Li, Ming-Shuang, Zhang, Qian, Shao, Yi-Ming, Huang, Li-Fang, Song, Yu-Dan, Huang, Yong, Zeng, Xiang, Liu, Li-Jun, Yang, Hong, Huang, Ao-Di, Bao, Li-Ming, Zheng, Hui, Ma, Chao, Lv, Xiao-Ya, Song, Lei, Ma, Zhao, Wang, Shu-Guang, Ma, Hao, Guan, Wei-Jie, Wu, Zhi-Yin, Zhong, Nan-Shan, Yin, Zun-Dong
• Format: Journal Article
• Language: English
• Published: United States Oxford University Press 11.08.2023
• Subjects: Adult; Asymptomatic infection; Asymptomatic Infections; Child, Preschool; China - epidemiology; Cohort analysis; Coronaviruses; COVID-19 - prevention & control; COVID-19 Vaccines; Humans; Infections; Major; Pneumonia; Retrospective Studies; Vaccine efficacy; China; vaccine effectiveness; homologous and heterologous booster; inactivated COVID-19 vaccines; China

Abstract Background China has been using inactivated coronavirus disease 2019 (COVID-19) vaccines as primary series and booster doses to protect the population from severe to fatal COVID-19. We evaluated primary and booster vaccine effectiveness (VE) against Omicron BA.2 infection outcomes. Methods...